Viridian Therapeutics Prices Upsized $350 Million Concurrent Public Offerings of Convertible Notes and Common Stock

Viridian Therapeutics Prices Upsized $350 Million Concurrent Public Offerings of Convertible Notes and Common Stock

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, announced the pricing of its upsized underwritten public offering of $225.0 million aggregate principal amount of its 1.75% convertible senior notes due 2032 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”) and its upsized underwritten public offering of 7,352,942 shares of its common stock at a public offering price of $17.00 per share  (the “Equity Offering”).

WilmerHale represented the underwriters in the public offerings.

The WilmerHale team was led by Lisa Firenze and included Glenn Pollner, Jeffries Oliver-Li, Kevin Cheng, and Whitley Horning, with assistance from Barish Ozdamar and Bruce Manheim.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link. (The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel